WeVote
Log In

Bill

Bill

SF 1307

Tobacco retailers requirement to offer for sale at leas one type of nicotine replacement therapy product

2025-2026 Regular Session Introduced by Liz Boldon and 1 co-sponsor

Minnesota bill requires tobacco retailers to stock at least one nicotine replacement therapy product to increase smoker access to evidence-based cessation aids at point of sale.

Author added Boldon
#commerceandcommercedepartment #tobaccoproducts
0
WeVote Research Nonpartisan
Bill Summary · SF 1307

Legislative bill overview

SF 1307 mandates that tobacco retailers in Minnesota stock at least one type of nicotine replacement therapy (NRT) product—such as patches, gum, lozenges, or nasal spray. This requirement applies to establishments licensed to sell tobacco products, creating a dual-product obligation for these retailers.

Why is this important

The bill addresses a public health gap by ensuring smokers have immediate access to evidence-based cessation aids at the point of sale where they purchase cigarettes. Research shows accessibility barriers reduce quit attempts, so co-locating NRT products with tobacco may increase cessation rates and reduce smoking-related disease burden.

Potential points of contention

  • Retail burden and feasibility: Smaller tobacco shops may face inventory management challenges, storage costs, and uncertainty about product demand and expiration timelines
  • Economic incentive misalignment: Retailers profit from tobacco sales; mandating competing cessation products may face industry resistance as unprofitable requirements
  • Regulatory scope and enforcement: Unclear how violations would be penalized, whether existing licensing mechanisms would enforce compliance, and whether exemptions exist for certain retail types

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.